# Biotel

> Biotel is a VC fund backing Biotechnology, Pharmaceutical and Health Care. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 2
- Last investment: May 2021
- Lead investor: 0%
- Last updated: Aug 2026

Biotel is a VC fund focused on Biotechnology and Pharmaceutical. Biotel

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 100% |
| Pharmaceutical | 2 | 100% |
| Health Care | 1 | 50% |
| Life Science | 1 | 50% |
| Therapeutics | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Series C | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Splisense | Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTRtranscripts according to the specific mutation carried. | $28.5M | Series B | May 13, 2021 |  |
| BioSight | BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantlyminimizing the systemic toxicity associated with conventional chemotherapy ​​treatments.​​​ | $27M | Series C | Dec 02, 2020 |  |

2 of 2 investments shown.

## Co-investors
- [Israel Biotech Fund](https://shizune.co/investors/profile/israel-biotechfund) — VC Fund, 2 deals together
- [Arkin Bio Ventures](https://shizune.co/investors/profile/arkin-bio-ventures) — VC Fund, 1 deal together
- [Integra Holdings](https://shizune.co/investors/profile/integra-holdings) — VC Fund, 1 deal together
- [Migdal Insurance and Financial Holdings](https://shizune.co/investors/profile/migdal-insurance-and-financial-holdings-ltd) — VC Fund, 1 deal together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 1 deal together
- [Phoenix Financial](https://shizune.co/investors/profile/phoenix-insurance-company) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Biotel invest in?

Biotel invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series B and Series C stage. Most of the 2 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Biotel last invest?

The most recent investment recorded for Biotel closed in May 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co